KLRS Q1 2021 Earnings — Kalaris Therapeutics Inc Revenue & Financial Results | Market Cap Arena

KLRSKalaris Therapeutics Inc

$180M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$18,000

Operating Income

-$31M

Net Income

-$31M

EPS (Diluted)

$-11.44

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$351M

Total Liabilities

$21M

Stockholders' Equity

$330M

Cash & Equivalents

$169M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$18,000	-$18,000	+0.0%
Operating Income	-$31M	-$10M	-213.6%
Net Income	-$31M	-$9M	-231.1%